Revolution Medicines, Inc.
RVMD
$76.76
$1.451.92%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 742.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 742.00K |
| Cost of Revenue | 675.48M | 564.72M | 558.37M | 470.64M | 419.13M |
| Gross Profit | -675.48M | -564.72M | -558.37M | -470.64M | -418.39M |
| SG&A Expenses | 156.57M | 127.77M | 108.90M | 96.72M | 87.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.04B | 897.50M | 789.43M | 689.52M | 628.44M |
| Operating Income | -1.04B | -897.50M | -789.43M | -689.52M | -627.70M |
| Income Before Tax | -961.73M | -812.81M | -698.26M | -600.85M | -566.72M |
| Income Tax Expenses | -753.00K | -753.00K | -753.00K | -753.00K | 343.00K |
| Earnings from Continuing Operations | -960.98 | -812.06 | -697.51 | -600.09 | -567.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -960.98M | -812.06M | -697.51M | -600.09M | -567.06M |
| EBIT | -1.04B | -897.50M | -789.43M | -689.52M | -627.70M |
| EBITDA | -1.03B | -890.70M | -782.75M | -683.00M | -621.56M |
| EPS Basic | -5.18 | -4.50 | -4.00 | -3.57 | -3.59 |
| Normalized Basic EPS | -3.24 | -2.82 | -2.50 | -2.23 | -2.13 |
| EPS Diluted | -5.18 | -4.50 | -4.00 | -3.57 | -3.59 |
| Normalized Diluted EPS | -3.24 | -2.82 | -2.50 | -2.23 | -2.13 |
| Average Basic Shares Outstanding | 739.72M | 717.33M | 693.89M | 670.47M | 637.90M |
| Average Diluted Shares Outstanding | 739.72M | 717.33M | 693.89M | 670.47M | 637.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |